STOCKS TELEGRAPH

Tag: iBio Inc.

  • IBIO Stocks Rally Amid Game-Changing AI Drug Discovery Deal

    IBIO Stocks Rally Amid Game-Changing AI Drug Discovery Deal

    iBio, Inc. (NYSE: IBIO) shares are experiencing a substantial surge of 127.83% this morning on the US stock market. At the latest check during the current session, IBIO shares were trading up at $2.62. This uptick in IBIO shares follows the announcement of a groundbreaking collaboration in AI-driven drug discovery.

    Today, iBio Inc. (IBIO) has disclosed its collaboration agreement with AstralBio, Inc. This collaboration aims to discover, engineer, and develop innovative antibodies targeting obesity and other cardiometabolic disorders.

    The objective of this transformative partnership is to swiftly establish an exceptional cardiometabolic disease portfolio by leveraging iBio’s proficiency in creating antibodies for challenging targets, combined with AstralBio’s extensive experience in biologics and drug development.

    Under this agreement, iBio has exclusively licensed its AI-powered technology to identify and engineer four targets for treating cardiometabolic diseases, with AstralBio responsible for advancing candidates through pre-clinical development to Investigational New Drug (IND) application stage.

    Additionally, iBio holds the exclusive option to license three cardiometabolic targets from AstralBio, with rights for development, manufacturing, and commercialization upon exercising this option.

    Consequently, iBio and AstralBio are commencing the development of a lead program targeting the transforming growth factor beta (TGFb) superfamily for addressing muscle wasting and obesity.

    The collaboration may also be expanded to include further targets in various fields by mutual agreement. IBIO expresses confidence in the potential of AI-enabled technology to develop antibodies against challenging targets in the cardiometabolic domain.

    The company envisions the future of treating millions affected by obesity and cardiometabolic diseases globally through next-generation therapies that improve both efficacy and tolerability profiles compared to current treatments.

    Notably, the lead program targeting the TGFb superfamily aims to achieve a best-in-class profile. IBIO anticipates announcing additional novel targets promising similarly transformative outcomes in the coming months.

    Furthermore, in an equity transaction, IBIO yesterday concluded a $15 million private placement financing with ADAR1 Capital Management, Lynx1 Capital Management, Ikarian Capital, and other institutional investors.

    A portion of the net proceeds will be allocated to supporting new partnerships, such as the collaboration with AstralBio.

  • What Caused IBIO Stock To Rise After Hours?

    What Caused IBIO Stock To Rise After Hours?

    At last check, shares of biotech innovator and biologics contract manufacturing organization iBio Inc. (IBIO) were up 7.19% to $1.49 in after-hours trading. Thursday’s closing price for IBIO stock was $1.39, up 4.51% from the previous day’s close. IBIO stock volume on the day was reduced to 6.36 million shares from 12.29 million shares in the past 50 days. Three new antibody programs support the company’s oncology drug discovery pipeline, driving IBIO stock higher.

    What program has IBIO started?

    iBio is a global leader in plant-based biologic production. In iBio’s FastPharming System, automated hydroponics, and novel glycosylation technologies are combined to produce monoclonal antibodies, vaccines, bioinks, and other proteins. iBio is developing biopharmaceuticals that treat cancers, as well as fibrotic and infectious diseases. iBio CDMO LLC, a subsidiary of the Company, provides Contract Development and Manufacturing Services to the FastPharming business, as well as Glycaneering services related to recombinant protein design.

    Announcing the addition of three anticancer targets to its pipeline of potential therapeutics, iBio, Inc. has taken another significant step towards harnessing the speed and throughput of its proprietary, plant-based FastPharming Protein Expression System.

    • With this enhancement, IBIO expands on its new drug discovery capabilities announced just a few weeks ago.
    • By partnering with best-in-class technology providers, IBIO intends to create the FastPharming System that will reduce the time and cost to move from initial concept to clinic, which will be part of its efforts to redefine the drug development paradigm.
    • FairJourney Biologics SA (“FairJourney”), a leader in antibody optimization, has agreed to provide research services to IBIO.
    • The deal provides IBIO with access to a proprietary antibody library and novel display technologies.
    • By combining its ‘speed-to-clinic’ advantages along with Glycaneering Technologies and FairJourney’s antibody optimization technologies, IBIO may be able to rapidly develop differentiated cancer therapeutic antibodies that will be more effective against cancer cells.
    • Several undisclosed IBIO collaborations are advancing rapidly towards the clinic as a result of its antibody discovery expertise in oncology.
    • The glycosylation techniques IBIO uses to enhance human anti-cancer antibody development will enable IBIO to change the bioprocess paradigm.

    What has IBIO accomplished?

    To complement the company’s previously offered contract development and manufacturing services, IBIO is adding its own in-house drug discovery capabilities. As a result of its plant-based FastPharming System, IBIO continues to reduce the lag times and costs associated with pharmaceutical development, and at the same time, to help develop its own biopharmaceuticals to address unmet medical needs in human health and veterinary medicine.

  • 35 stocks making the biggest moves premarket today

    35 stocks making the biggest moves premarket today

    FuelCell Energy Inc. (FCEL) stock soared 4.75% to $10.15 in the pre-market trading. The most recent rating by JP Morgan, on November 19, 2020, is a Neutral.

    SCWorx Corp. (NASDAQ: WORX) shares are trading down -6.76% at $2.07 at the time of writing. Company’s 52-week ranged between $1.00 to $14.88.

    Nano Dimension Ltd. (NNDM) lost over -12.1% at $5.74 in pre-market trading Monday, November 30, 2020, after announcing that it has entered into definitive agreements with investors for the sale of 11,960,160 of the Company’s American Depositary Shares (“ADSs”) at a price of $5.00 per ADS pursuant to a registered direct offering.

    Moderna Inc. (MRNA) is up more than 9.38% at $138.95 in pre-market hours on Monday, November 30, 2020 after the firm today announced that the primary efficacy analysis of the Phase 3 study of mRNA-1273 conducted on 196 cases confirms the high efficacy observed at the first interim analysis. The data analysis indicates a vaccine efficacy of 94.1%. The stock had jumped over 16.35% to $127.03 in the last trading session.

    FreightCar America Inc. (NASDAQ: RAIL) shares are trading down -3.99% at $2.65 at the time of writing. Company’s 52-week ranged between $0.73 to $2.87. Analysts have a consensus price target of $4.50.

    Blink Charging Co. (BLNK), a Specialty Retail company, dropped about -3.25% at $27.09 in pre-market trading Monday. The firm recently declared that it has acquired the EV charging operator U-Go Stations, Inc. and its portfolio of 44 DCFC charging locations.

    Zomedica Corp. (ZOM), a Drug Manufacturers – Specialty & Generic company, dropped about -1.12% at $0.1324 in pre-market trading Monday.

    GameStop Corp. (GME) is up more than 4.1% at $16.74 in pre-market hours Monday November 30, 2020 after declaring 2020 cyber week deals. The stock had jumped over 9.02% to $16.08 in the last trading session. GameStop Announces 2020 Cyber Week Deals.

    Riot Blockchain Inc. (RIOT) grew over 8.64% at $6.79 in pre-market trading today.

    Verastem Inc. (VSTM) stock moved up 5.03 percent to $2.09 in the pre-market trading after reporting the initiation of a Phase 2 registration-directed clinical trial of VS-6766, its RAF/MEK inhibitor, and defactinib, its FAK inhibitor, in patients with recurrent low-grade serous ovarian cancer (LGSOC).

    Tuniu Corporation (TOUR) gained over 6.58% at $3.4 in pre-market trading on Monday, November 30, 2020. Before the trading started on November 30, 2020.

    Novavax Inc. (NVAX) is down -8.31% to reach $115.25 after providing an update on its COVID-19 vaccine program. NVX‑CoV2373 is a stable, prefusion protein antigen derived from the genetic sequence of the SARS-CoV-2 coronavirus spike (S) protein and adjuvanted with Novavax’ proprietary Matrix‑M™. It has been trading in a 52-week range of $3.65 to $189.40.

    Occidental Petroleum Corporation (NYSE: OXY) shares are trading down -2.36% at $16.17 at the time of writing. Company’s 52-week ranged between $8.52 to $47.58. Analysts have a consensus price target of $18.

    RMG Acquisition Corp. (RMG) stock soared 6.6% to $18.1 in the pre-market trading. The firm recently revealed that the close of business on Tuesday, December 1, 2020, has been set as the record date for the determination of stockholders eligible to receive the proxy and vote at the special meeting to be held to consider and approve the previously announced merger with Romeo Systems, Inc., a Delaware corporation.

    Uxin Limited (UXIN) stock soared 2.53% to $1.62 in the pre-market trading. The most recent rating by JP Morgan, on October 23, 2019, is a Neutral.

    ReneSola Ltd (NYSE: SOL) shares are trading up 8.02% at $8.08 at the time of writing. The technology company recently announced the closing of the sale of a portfolio of operating projects located in the United Kingdom to Atmosclear Investments Ltd, an European renewable energy and cleantech private equity group. Company’s 52-week ranged between $0.85 to $5.67. Analysts have a consensus price target of $22.

    Kandi Technologies Group Inc. (KNDI) tumbled over -2.28% at $13.31 in pre-market trading today after CBAK Energy and Kandi Group signed a supply framework agreement.

    Vaxart Inc. (VXRT) is up more than 4.84% at $7.37 in pre-market hours on Monday, November 30, 2020. The stock had jumped over 9.84% to $7.03 in the last trading session. Before the trading started on November 30, 2020.

    Alibaba Group Holding Limited (BABA) is down -2.3% to reach $270.13. The internet retail company has been named a leader in Gartner’s 2020 Magic Quadrant for Cloud Database Management Systems. It has been trading in a 52-week range of $169.95 to $319.32.

    EyePoint Pharmaceuticals Inc. (EYPT) stock soared 1.97% to $0.55 in the pre-market trading. The most recent rating by B. Riley FBR, on April 06, 2020, is a Neutral.

    Canaan Inc. (NASDAQ: CAN) shares are trading down -7.83% at $5.3 at the time of writing after releasing its unaudited financial results for the three months ended September 30, 2020. Company’s 52-week ranged between $1.76 to $8.69.

    Heat Biologics Inc. (NASDAQ: HTBX) shares are trading down -0.88% at $1.13 at the time of writing. Company’s 52-week ranged between $0.19 to $4.30. Analysts have a consensus price target of $4.

    Yunji Inc. (YJ), an Internet Retail company, dropped about -7.35% at $3.53 in pre-market trading Monday. The firm recently declared its unaudited financial results for the third quarter ended September 30, 2020.

    India Globalization Capital Inc. (IGC) gained over 22.63% at $2.33 in pre-market trading Monday November 30, 2020.

    Oramed Pharmaceuticals Inc. (ORMP) stock moved up 38.65 percent to $6.17 in the pre-market trading. The healthcare firm recently reported that it has screened the first patients in its global Phase 3 trials of its oral insulin capsule ORMD-0801 for the treatment of type 2 diabetes (T2D). Before the trading started on November 30, 2020.

    Schlumberger Limited (SLB) is down -2.06% to reach $21.43. It has been trading in a 52-week range of $11.87 to $41.14.

    Ocugen Inc. (OCGN) stock plunged -1.71% to $0.294 in the pre-market trading. The firm recently revealed that Dr. Shankar Musunuri, Chairman, CEO, and Co-Founder of Ocugen, will speak on “The Promise of Cell & Gene Therapies: Regulatory and Reimbursement Roadblocks” at Xconomy’s Xcelerating Life Sciences New York & Philadelphia Virtual Event on December 3 at 10:30 a.m. Before the trading started on November 30, 2020.

    Gold Fields Limited (GFI) is down -2.52% to reach $8.5. It has been trading in a 52-week range of $3.79 to $14.90. Before the trading started on November 30, 2020.

    Marathon Patent Group Inc. (MARA) is up 15.65% to reach $4.95. It has been trading in a 52-week range of $0.35 to $6.05.

    Kingsoft Cloud Holdings Limited (KC) stock soared 5.13% to $43.69 in the pre-market trading after reporting that it will be included in the MSCI China Index, effective after the U.S. market close on November 30, 2020. The most recent rating by Goldman, on June 29, 2020, is a Buy.

    NanoVibronix Inc. (NASDAQ: NAOV) shares are trading up 5.26% at $0.8 at the time of writing. Company’s 52-week ranged between $0.54 to $3.50.

    Waitr Holdings Inc. (WTRH) stock moved down -1.46 percent to $3.38 in the pre-market trading.

    Hennessy Capital Acquisition Corp. IV (HCAC) gained over 9.0% at $13.69 in pre-market trading on Monday, November 30, 2020.

    Trevena Inc. (TRVN) stock plunged -4.67% to $2.45 in the pre-market trading. The most recent rating by Guggenheim, on September 14, 2020, is a Buy.

    Suncor Energy Inc. (NYSE: SU) shares are trading down -0.58% at $17.15 at the time of writing. The firm lately publicized that it, together with the other Syncrude joint venture owners – Imperial Oil Resources Limited, CNOOC Oil Sands Canada, and Sinopec Oil Sands Partnership – have agreed in principle for Suncor to become the operator of the Syncrude project by the end of 2021. Company’s 52-week ranged between $9.60 to $34.56.

  • 23 stocks making the biggest moves in the premarket today

    23 stocks making the biggest moves in the premarket today

    DPW Holdings Inc. (DPW) stock soared 2.5% to $7.37 in the pre-market trading after the company revealed that its power electronics business, Coolisys Technologies Corp., has established a program targeting both national and regional fast-food franchises to install the ACECool™ electric vehicle (“EV”) chargers as a part of a revenue sharing program.

    Naked Brand Group Limited (NASDAQ: NAKD) shares are trading up 9.19% at $0.2008 at the time of writing. Company’s 52-week ranged between $0.07 to $4.00.

    Ideanomics Inc. (IDEX) grew over 15.27% at $3.02 in pre-market trading today. The firm reported that it has increased its stake in California-based Solectrac, Inc. through a follow-on investment of an additional $1.3 million.

    Sundial Growers Inc. (SNDL), a Drug Manufacturers – Specialty & Generic company, rose about 72.38% at $0.4151 in pre-market trading Tuesday. The company recently publicized that it will participate in Cowen’s 2020 Boston Cannabis Conference, to be held virtually between November 30 and December 2, 2020.

    Li Auto Inc. (NASDAQ: LI) shares are trading up 6.99% at $46.69 at the time of writing. Company’s 52-week ranged between $14.31 to $40.81. Analysts have a consensus price target of $45.60.

    Tantech Holdings Ltd (TANH) grew over 23.36% at $2.64 in pre-market trading today following the firm declared that it has entered into a securities purchase agreement with institutional investors to purchase approximately $10 million of its common shares and registered warrants to purchase common shares in a registered direct offering as well as unregistered warrants to purchase common shares in a concurrent private placement.

    Marathon Patent Group Inc. (MARA), a Capital Markets company, rose about 16.26% at $5.72 in pre-market trading Tuesday.

    Ayro Inc. (AYRO) lost over -5.75% at $9.99 in pre-market trading Tuesday November 24, 2020 after the firm revealed that it has entered into definitive agreements with Carnegie Hudson Resources, an investment arm of Wanxiang America, and several existing institutional investors.

    Carnival Corporation & Plc (CCL) is up more than 6.49% at $19.36 in pre-market hours Tuesday November 24, 2020 after the recent declaration that the company has closed its previously announced registered direct offering of 10.4 million shares of its common stock at a price of $17.59 per share to a holder of its 5.75% Convertible Senior Notes due 2023.  The stock had jumped over 4.66% to $18.18 in the last trading session.

    Before the trading started on November 24, 2020, Occidental Petroleum Corporation (OXY) is up 7.42% to reach $16.93. It has been trading in a 52-week range of $8.52 to $47.58.

    Fuel Tech Inc. (FTEK) stock soared 57.45% to $4.44 in the pre-market trading. The most recent rating by H.C. Wainwright, on March 13, 2020, is a Neutral.

    Kandi Technologies Group Inc. (NASDAQ: KNDI) shares are trading up 8.17% at $16.15 at the time of writing as the firm publicized that it closed the registered direct offering of 8,849,560 units (the “Units”) of its securities at a purchase price per Unit of $11.30 on November 23, 2020, as previously announced on November 20, 2020. Company’s 52-week ranged between $2.17 to $17.40.

    Tilray Inc. (TLRY) grew over 19.31% at $7.97 in pre-market trading today after company’s publication that it has entered into a privately negotiated exchange agreement with a certain holder of its 5.00% Convertible Senior Notes due 2023.

    Barrick Gold Corporation (GOLD), a Gold company, dropped about -2.67% at $22.62 in pre-market trading Tuesday after Loncor Resources provided an update on its exploration activities within the Ngayu greenstone belt, where the Company has a joint venture with Barrick Gold (DRC) Limited as well as its own majority-owned projects.

    Switchback Energy Acquisition Corporation (SBE) grew over 20.04% at $40.91 in pre-market trading today.

    iBio Inc. (IBIO), a Biotechnology company, dropped about -3.4% at $1.42 in pre-market trading Tuesday. The healthcare company recently reported that the United States Patent and Trademark Office has issued U.S. Patent No. 10,844,392, entitled “Materials and Methods for Producing Endostatin Fusion Polypeptides in Plant Cells,” which, amongst other claims, covers a novel expression cassette that enhances the yield of endostatin fragments and variants using iBio’s FastPharming® System.

    Ferroglobe PLC (GSM) stock moved down -13.67 percent to $1.2 in the pre-market trading after the firm declared results for the third quarter of 2020.

    Longview Acquisition Corp. (LGVW) stock soared 24.26% to $16.9 in the pre-market trading.

    Ocean Power Technologies Inc. (NASDAQ: OPTT) shares are trading up 43.32% at $3.11 at the time of writing after the firm proclaimed that Jorge Franco has joined the Company as Regional Sales Representative based in Spain. Reporting to OPT Vice President, Global Sales Jeff Wiener, Mr. Franco will concentrate on opportunities in Southern Europe. Company’s 52-week ranged between $0.33 to $3.72.

    Kosmos Energy Ltd. (KOS) grew over 8.95% at $2.07 in pre-market trading today.

    Before the trading started on November 24, 2020, Ballard Power Systems Inc. (BLDP) is down -3.75% to reach $20.77 following announcement of US$250 million bought deal offering of common shares by the company. It has been trading in a 52-week range of $5.50 to $21.61.

    Bloom Energy Corporation (BE) stock soared 8.61% to $23.98 in the pre-market trading. The most recent rating by Raymond James, on February 20, 2020, is a Mkt perform.

    Energous Corporation (WATT) stock soared 9.13% to $2.51 in the pre-market trading. The most recent rating by Ladenburg Thalmann, on May 01, 2019, is a Buy.

    Canaan Inc. (NASDAQ: CAN) shares are trading up 7.31% at $5.43 at the time of writing. The technology company recently told that it will release its third-quarter 2020 financial results before the market opens on Monday, November 30, 2020. The company’s 52-week ranged between $1.76 to $13.00.

  • What changed for these 46 stocks in Pre Market Session?

    What changed for these 46 stocks in Pre Market Session?

    Alterity Therapeutics Limited (ATHE) stock plunged -10.31% to $2.0 in the pre-market trading after the company announced the approval of a US patent for the next generation.

    Cinedigm Corp. (NASDAQ: CIDM) shares are trading down -4.55% at $0.525 at the time of writing after it posted Second Quarter Fiscal 2021 Earnings. The company’s 52-week range was noted as $0.25 to $6.00. Analysts have a consensus price target of $3.50.

    iBio Inc. (IBIO) tumbled over -2.34% at $1.67 in pre-market trading today as the Company revealed fiscal first quarter 2021 Financial results and provides a business update.

    CBAK Energy Technology Inc. (CBAT), an Electrical Equipment & Parts company, dropped about -7.4% at $9.01 in pre-market trading Wednesday.

    Comstock Mining Inc. (LODE) stock moved down -1.96 percent to $1.0 in the pre-market trading as it revealed to Host Earnings Call.

    CureVac N.V. (CVAC) lost over -3.01% at $74.19 in pre-market trading Wednesday 18 November 2020 after the news that the Company has established a European-based network to ramp Up manufacturing of its COVID-19 vaccine candidate, CVnCoV.

    Oncternal Therapeutics Inc. (ONCT) is down more than -24.88% at $3.11 in pre-market hours Wednesday 18 November 2020 as the Company increases previously revealed bought deal to $22.5 million. The stock had dropped over -9.41% to $4.14 in the last trading session.

    Before the trading started on 18 November 2020, New Concept Energy Inc. (GBR) is down -11.38% to reach $1.48 after the firm announced its Q3, 2020 results. It has been trading in a 52-week range of $0.55 to $2.19.

    Polar Power Inc. (POLA) stock plunged -7.25% to $3.07 in the pre-market trading. The most recent rating by ROTH Capital, on November 07, 2017, is at a Neutral.

    Trinity Biotech plc (NASDAQ: TRIB) shares are trading down 0.0% at $2.9 at the time of writing. The company’s 52-week range was noted as $0.56 to $3.35 as the company set to Host an Earnings Call.

    So-Young International Inc. (SY) grew over 4.65% at $13.5 in pre-market trading today as the company said it is going to report its earnings to result on November 25, 2020.

    BioNTech SE (BNTX), a Biotechnology company, rose about 4.22% at $90.6 in pre-market trading Wednesday after the report that Pfizer and BioNTech planned to file as vaccine proves 95% effective.

    Sunworks Inc. (SUNW) stock moved down -4.91 percent to $3.68 in the pre-market trading after the Company revealed that the proposed merger with the Peck Company Holdings, Inc. failed to secure stockholder approval.

    Sundial Growers Inc. (SNDL) lost over -3.04% at $0.2424 in pre-market trading Wednesday 18 November 2020 following the announcement of its third-quarter earnings results.

    Tuniu Corporation (TOUR) is up more than 1.04% at $1.95 in pre-market hours Wednesday 18 November 2020. The stock had dropped over -3.98% to $1.93 in the last trading session.

    Before the trading started on 18 November 2020, Taiwan Semiconductor Manufacturing Company Limited (TSM) is up 3.22% to reach $98.79 following the report that Samsung heats up chip wars with the claim that it can catch TSMC by 2022. It has been trading in a 52-week range of $42.70 to $102.44.

    Hill International Inc. (HIL) stock plunged -5.49% to $1.55 in the pre-market trading as the company said that CEO Raouf Ghali and CFO Todd Weintraub are scheduled to present at the following investor conferences during the month of November.

    Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) shares are trading down -4.77% at $0.5615 at the time of writing after the preliminary results following vaccination of non-human primates with TNX-1800 a live attenuated COVID-19 vaccine candidate engineered to express the SARS-CoV-2 spike protein after vaccination. The company’s 52-week range was noted as $0.39 to $2.46. Analysts have a consensus price target of $4.

    Genius Brands International Inc. (GNUS) tumbled over -3.42% at $1.13 in pre-market trading today after the company revealed strategic takeover of ChizComm Ltd. and ChizComm Beacon Media.

    Medley Management Inc. (MDLY), an Asset Management company, rose about 33.73% at $9.0 in pre-market trading Wednesday announced third-quarter earnings results.

    China SXT Pharmaceuticals Inc. (SXTC) stock moved down -3.59 percent to $0.2603 in the pre-market trading.

    Camtek Ltd. (CAMT) lost over -3.64% at $19.05 in pre-market trading Wednesday 18 November 2020 following the news of the commencement of a proposed underwritten public offering of three million ordinary shares.

    Cellectis S.A. (CLLS) is up more than 5.58% at $20.8 in pre-market hours Wednesday 18 November 2020, after the firm announced the appointment of Kyung Nam-Wortman as Cellectis’ Executive Vice President, Chief Human Resources Officer. The stock had dropped over -1.79% to $19.70 in the last trading session.

    Before the trading started on 18 November 2020, TechnipFMC plc (FTI) is up 4.34% to reach $8.42 after the Company received notice to proceed with the EPC contract for Sempra LNG’s and IEnova’s Energía Costa Azul LNG facility. It has been trading in a 52-week range of $4.49 to $21.84.

    Li Auto Inc. (LI) stock soared 3.17% to $36.16 in the pre-market trading after the Company revealed the 3rd quarter of 2020 Earnings results. The most recent rating by Citigroup, on November 16, 2020, is at a Buy.

    BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) shares are trading down -2.47% at $2.76 at the time of writing. The company’s 52-week range was noted as $2.35 to $62.00.

    Neptune Wellness Solutions Inc. (NEPT) tumbled over -2.63% at $1.85 in pre-market trading today after the company posted 2nd quarter loss and missed the predictions.

    Livent Corporation (LTHM), a Specialty Chemicals company, rose about 4.19% at $15.9 in pre-market trading Wednesday following the report of Analysts revised their forecast after disappointing Earnings.

    Micro Focus International plc (MFGP) stock moved up 29.73 percent to $4.8 in the pre-market trading.

    Houghton Mifflin Harcourt Company (HMHC) gained over 5.63% at $3.0 in pre-market trading Wednesday 18 November 2020 after the Company announced financial results for the quarter ended September 30, 2020. The Company revealed its plan to explore the potential sale of HMH Books & Media, its Consumer Publishing business.

    Acasti Pharma Inc. (ACST) is up more than 3.81% at $0.218 in pre-market hours Wednesday 18 November 2020 as the Company offered a business update for Q2, 2020. The stock had jumped over 0.77% to $0.21 in the last trading session.

    Before the trading started on 18 November 2020, Canaan Inc. (CAN) is up 8.73% to reach $3.61. It has been trading in a 52-week range of $1.76 to $13.00.

    VAALCO Energy Inc. (EGY) stock soared 45.1% to $1.48 in pre-market trading.

    Liminal BioSciences Inc. (NASDAQ: LMNL) shares are trading up 11.37% at $4.31 at the time of writing posted third-quarter results. The company’s 52-week range was noted as $3.51 to $31.45.

    Carver Bancorp Inc. (CARV) grew over 3.89% at $6.95 in pre-market trading today.

    Vaxart Inc. (VXRT), a Biotechnology company, dropped about -2.47% at $5.53 in pre-market trading Wednesday after it publicized that it is set to host a Key Opinion Leader (KOL) panel for investors entitled “An Oral Tablet Vaccine – A Potential Global Solution to COVID-19 and Norovirus?” on Thursday, November 19, 2020, at 12pm Eastern Time.

    SCWorx Corp. (WORX) stock moved down -3.64 percent to $1.06 in the pre-market trading.

    Sunoco LP (SUN) lost over -7.0% at $27.11 in pre-market trading Wednesday 18 November 2020 as the Company gained above 5% as Q3 Earnings topped predictions.

    NIO Limited (NIO) is up more than 3.78% at $48.35 in pre-market hours Wednesday 18 November 2020 as the Company revealed its Q3 loss less than expected, whiles sales topped predictions. The stock had jumped over 2.22% to $46.59 in the last trading session.

    Before the trading started on 18 November 2020, Ocugen Inc. (OCGN) is up 4.27% to reach $0.3029 as Company recently revealed Q3 results. It has been trading in a 52-week range of $0.17 to $0.96.

    Weidai Ltd. (WEI) stock soared 9.4% to $1.63 in the pre-market trading after the report that the Company regained compliance after receipt of NYSE Non-compliance letter regarding ADS trading price on October 20, 2020. The most recent rating by Morgan Stanley, on January 21, 2020, is at an Underweight.

    Magnolia Oil & Gas Corporation (NYSE: MGY) shares are trading up 2.99% at $6.2 at the time of writing after the Company missed Earnings predictions. The company’s 52-week range was noted as $3.23 to $13.28.

    Waitr Holdings Inc. (WTRH) grew over 13.68% at $3.24 in pre-market trading today as the Company beat the Earnings outlook.

    Norwegian Cruise Line Holdings Ltd. (NCLH), a Travel Services company, dropped about -6.17% at $20.7 in pre-market trading Wednesday after the company revealed the pricing of 40,000,000 ordinary shares.

    IZEA Worldwide Inc. (IZEA) stock moved up 5.49 percent to $0.77 in the pre-market trading as it revealed Q3 financial results.

    The Boeing Company (BA) gained over 3.53% at $217.46 in pre-market trading Wednesday 18 November 2020 after the report that Boeing’s 737 Max cleared to fly in the US after crashes.

     

  • 18 Biotech Stocks That Are Great Options To Invest In

    18 Biotech Stocks That Are Great Options To Invest In

    The biotech industry is considered to be an attractive industry for the investor. This industry is continuously adopting new technological advancements. As time passes by every aspect of daily existence experience changes because of new technological breakthroughs and advancement in knowledge. Technology plays an important role in changing the lifestyle of humans. This technology also plays a very important role in the biotech industry.

    This technology has historically grown quickly. The biotech industry is striving to develop a treatment for complex diseases. It is anticipated that in 2021, one of the continuing trends in biotech is the continued improvement and development of drug research. The new technology help researchers to improve and assess diagnosis and treatment using medications.

    Check out the top 18 biotech companies you should add to your portfolio:

    BioLineRx Ltd. (NASDAQ: BLRX)

    BioLineRx Ltd. (NASDAQ: BLRX) shares were trading up 33.78% at $1.98 at the time of writing on Friday. BioLineRx Ltd. (NASDAQ: BLRX) share price went from a low point around $1.06 to briefly over $3.04 in the past 52 weeks, though shares have since pulled back to $1.98. BLRX market cap has remained high, hitting $39.57M at the time of writing. BioLineRx Ltd. (BLRX) has earlier announced the promising results from the ongoing GENESIS Phase III trial motixafortide for stem cell mobilization (SCM) in multiple myeloma patients.

    Miragen Therapeutics Inc. (NASDAQ: MGEN)

    Miragen Therapeutics Inc. (NASDAQ: MGEN) last closed at $1.31, in a 52-week range of $0.31 to $2.27. Miragen Therapeutics Inc. (MGEN) has earlier acquired  Viridian Therapeutics, Inc. It has traded up 321.22% and traded down -42.29% from its 52-weeks high. Looking at its liquidity, it has a current ratio of 4.80 and a quick ratio of 4.80. This company has a market capitalization of $79.29 million at the time of writing.

    Equillium Inc. (NASDAQ: EQ)

    Equillium Inc. (NASDAQ: EQ) stock soar by 5.83% to $6.35. The most recent rating by H.C. Wainwright, on July 14, 2020, is at a Buy. Previously, Equillium Inc. (EQ) has revealed that it has received a ‘Study May Proceed letter’ from the U.S. Food and Drug Administration (FDA) to commence a Phase 3 clinical trial, titled  EQUINOX, evaluating itolizumab in hospitalized COVID-19 patients suffering from acute respiratory distress syndrome (ARDS).

    Titan Pharmaceuticals Inc. (NASDAQ: TTNP)

    Titan Pharmaceuticals Inc. (NASDAQ: TTNP) shares headed falling, lower as much as -3.24%. The most recent rating by Maxim Group, on June 26, 2019, is at a Buy. Titan Pharmaceuticals Inc. (TTNP) revealed the pricing of an underwritten public offering of 80,000,000 units at a price of $0.10 per unit. Each unit issued in the offering comprised of one share of common stock and one warrant to purchase one share of common stock.

    Trevena Inc. (NASDAQ: TRVN)

    Trevena Inc. (NASDAQ: TRVN) rose 2.34% after gaining more than $0.06 on Friday. Trevena Inc. (TRVN) has disclosed that oliceridine has been classified as a Schedule II controlled substance by the U.S. Drug Enforcement Administration (DEA). Looking at its liquidity, it has a current ratio of 16.20 and a quick ratio of 16.20. This company has a market capitalization of $381.29 million at the time of writing.

    Sorrento Therapeutics Inc. (NASDAQ: SRNE)

    Sorrento Therapeutics Inc. (NASDAQ: SRNE) last closed at $6.94, in a 52-week range of $1.45 to $19.39. Sorrento Therapeutics Inc. (SRNE) has earlier announced preclinical data about intravenous COVI-AMG™ (STI-2020; Affinity Matured COVI-GUARD) neutralizing antibody (nAb) in a preprint publication.

    iBio Inc. (AMEX: IBIO)

    iBio Inc. (AMEX: IBIO) shares headed falling, lower as much as -1.69%. The most recent rating by Alliance Global Partners, on June 26, 2020, is at a Buy. iBio Inc. (IBIO) has earlier appointed Dr. Alexandra Kropotova to its Board of Directors, effective as of October 14, 2020. Dr. Kropotova has also been chosen as a member of iBio’s new Science & Technology Committee, which shall be chaired by Dr. Philip Russell.

    Inovio Pharmaceuticals Inc. (NASDAQ: INO)

    Inovio Pharmaceuticals Inc. (NASDAQ: INO) fall -6.10% after losing more than -$0.64 on Friday. Inovio Pharmaceuticals Inc. (INO) announced that it is scheduled to release its third-quarter financial results of 2020 on November 9, 2020.  This company has a market capitalization of $1.76 billion at the time of writing.

    Vaxart Inc. (NASDAQ: VXRT)

    Vaxart Inc. (NASDAQ: VXRT) last closed at $4.92, in a 52-week range of $0.27 to $17.49. A class action has started on behalf of certain shareholders in Vaxart, Inc. It has traded up 1749.62% and traded down -71.87% from its 52-weeks high. Looking at its liquidity, it has a current ratio of 4.00 and a quick ratio of 4.00. This company has a market capitalization of $580.22 million at the time of writing.

    Axovant Gene Therapies Ltd. (NASDAQ: AXGT)

    Axovant Gene Therapies Ltd. (NASDAQ: AXGT) stock drop by -41.64% to $2.13. The most recent rating by Cantor Fitzgerald, on April 17, 2020, is at an Overweight. Axovant Gene Therapies Ltd. (AXGT) has earlier announced program updates on Friday, October 30, 2020, at 11:30 AM Eastern time, for the Company’s AXO-Lenti-PD gene therapy for Parkinson’s disease.

    Akebia Therapeutics Inc. (NASDAQ: AKBA)

    Akebia Therapeutics Inc. (NASDAQ: AKBA) shares headed falling, lower as much as -2.20%. The most recent rating by Needham, on November 14, 2019, is at a Buy. Akebia Therapeutics Inc. (AKBA) earlier revealed that it is scheduled to announce its financial results for the third quarter ended September 30, 2020, on November 5, 2020, before the opening of the market.

    Moderna Inc. (NASDAQ: MRNA)

    Moderna Inc. (NASDAQ: MRNA) fall -5.35% after losing more than -$3.81 on Friday. Moderna Inc. (MRNA) earlier revealed that it has been recognized as one of the global biopharmaceutical industry’s top employers in Science and ScienceCareers’ 2020 Top Employers Survey for the sixth consecutive year.

    Heat Biologics Inc. (NASDAQ: HTBX)

    Heat Biologics Inc. (NASDAQ: HTBX) stock soar by 3.45% to $1.20. The most recent rating by B. Riley Securities, on October 14, 2020, is at a Buy. Heat Biologics Inc. (HTBX) share price went from a low point around $0.19 to briefly over $4.30 in the past 52 weeks, though shares have since pulled back to $1.20. HTBX market cap has remained high, hitting $172.30 Million at the time of writing.

    Onconova Therapeutics Inc. (NASDAQ: ONTX)

    Onconova Therapeutics Inc. (NASDAQ: ONTX) last closed at $0.26, in a 52-week range of $0.10 to $1.56. Onconova Therapeutics Inc. (ONTX) revealed that Dr. Steven M. Fruchtman, President and Chief Executive Officer, will present a company update during the 2020 BIO Investor Forum Digital event taking place October 13-15.

    Clovis Oncology Inc. (NASDAQ: CLVS)

    Clovis Oncology Inc. (NASDAQ: CLVS) stock drop by -4.27% to $4.93. The most recent rating by H.C. Wainwright, on May 18, 2020, is at a Buy. Clovis Oncology Inc. (CLVS) is scheduled to release its third-quarter 2020 financial results on Thursday, November 5, 2020, before the open of the U.S. financial markets. Clovis’ senior management will host a conference call and live audio webcast at 8:30 a.m.

    BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX)

    BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX) shares headed rising, higher as much as 2.41%. The most recent rating by JP Morgan, on September 29, 2020, is at an Overweight. BioCryst Pharmaceuticals Inc. (BCRX) revealed that the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has granted oral, once-daily berotralstat a positive scientific opinion through the Early Access to Medicines Scheme (EAMS).

    Soligenix Inc. (NASDAQ: SNGX)

    Soligenix Inc. (NASDAQ: SNGX) rose 0.59% after gaining more than $0.01 on Friday. Soligenix Inc. (SNGX) has disclosed that continued optional treatment with SGX301 across all lesions during the compassionate use, safety portion of the trial (Cycle 3), for a total of 6 months in the study, continued to significantly improve responses and remained safe and well-tolerated in its FLASH study.

    Scholar Rock Holding Corporation (SRRK)

    Scholar Rock Holding Corporation (SRRK) last closed at $38.90, in a 52-week range of $6.95 to $46.50. Analysts have a consensus price target of $30.00. Scholar Rock Holding Corporation (SRRK) announced the pricing of an underwritten public offering of 2,948,718 shares of its common stock at a public offering price of $39.00 per share.

  • Here’s Why You Should Hold These 15 Biotech Stocks

    Here’s Why You Should Hold These 15 Biotech Stocks

    The biotechnology industry is considered to be an attractive industry for investors as the investors are always looking for safe and secure investments. This industry is a good option for investors as it is a strong and profitable industry. Companies in the biotechnology industry are continuously striving and exploring treatment for rare diseases. This industry has a significant contribution to the well-being of society. The biotechnology industry is constantly experiencing tech improvements and new scientific discoveries.

    Technology has always been at the heart of the biotechnology industry. New technological advancements are helpful for the biotechnology industry. This industry is anticipated to show a higher growth rate over the period of the next seven years. Globally, it is predicted that this industry will generate massive revenue in the coming years and it will also provide investment opportunities to investors who want to invest in the research and development of this industry.

    The following are the leading companies in the biotechnology industry. Let check how these companies are providing the best services to their clients:

    Sorrento Therapeutics Inc. (NASDAQ: SRNE)

    Sorrento Therapeutics Inc. (NASDAQ: SRNE) shares were trading down -10.49% at $9.30 at the time of writing on Friday. Sorrento Therapeutics Inc. (NASDAQ: SRNE) share price went from a low point around $1.45 to briefly over $19.39 in the past 52 weeks, though shares have since pulled back to $9.30. SRNE market cap has remained high, hitting $2.72B at the time of writing, giving it a price-to-sales ratio of more than 70.

    Sorrento Therapeutics Inc. (SRNE) has announced earlier that it has secured the receipt of clearance from a Brazilian regulatory agency to continue with a Phase 2 clinical trial of Abivertinib in mild, moderate, and severe COVID-19 patients. If we look at the recent analyst rating SRNE, H.C. Wainwright reiterated coverage on SRNE shares with a Buy rating.

    EyePoint Pharmaceuticals Inc. (NASDAQ: EYPT)

    EyePoint Pharmaceuticals Inc. (EYPT) last closed at $0.48, in a 52-week range of $0.46 to $2.69. EyePoint Pharmaceuticals Inc. (EYPT) revealed changes to its existing debt facility with CRG Servicing LLC (CRG). Under the terms of the amendment, CRG has waived the covenant associated with the Company’s net product revenue of DEXYCU and YUTIQ for the twelve-month period ending on December 31, 2020.

    Vaxart Inc. (NASDAQ: VXRT)

    Vaxart Inc. (VXRT) stock drop by -3.49% to $6.08. The most recent rating by H.C. Wainwright, on August 12, 2020, is at a Buy. The Schall Law Firm disclosed that the class-action lawsuit has been lodged against Vaxart, Inc. (VXRT)  for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

    Novan Inc. (NASDAQ: NOVN)

    Novan Inc. (NASDAQ: NOVN) shares headed falling, lower as much as -4.59%. The most recent rating by Piper Jaffray, on January 06, 2020, is at a Neutral. Novan Inc. (NOVN) revealed earlier that the positive in vitro results exhibited the potential efficacy of its NITRICIL™ platform technology as an antiviral against SARS-CoV-2, the virus that causes COVID-19.

    Akebia Therapeutics Inc. (NASDAQ: AKBA)

    Akebia Therapeutics Inc. (NASDAQ: AKBA) rose 3.42% after gaining more than $0.13 on Friday. Akebia Therapeutics Inc. (AKBA) revealed that it is scheduled to present data from its global Phase 3 programs of vadadustat for the treatment of anemia due to chronic kidney disease (CKD) in adult patients on dialysis ) and not on dialysis at the American Society of Nephrology Kidney Week 2020 Reimagined (ASN Kidney Week) on October 22 – 25, 2020.

    Royalty Pharma plc (NASDAQ: RPRX)

    Royalty Pharma plc (RPRX) last closed at $41.81, in a 52-week range of $38.54 to $56.50. Analysts have a consensus price target of $52.67. Royalty Pharma plc (RPRX) disclosed today that it is scheduled to announce its third-quarter 2020 financial results on Wednesday, November 11, 2020, before the U.S. financial markets open.

    Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX)

    Vertex Pharmaceuticals Incorporated (VRTX) stock soar by 1.30% to $218.08. The most recent rating by H.C. Wainwright, on July 31, 2020, is at a Buy. Vertex Pharmaceuticals Incorporated (VRTX) shared an update on its clinical programs targeting the small molecule correction of alpha-1 antitrypsin deficiency (AATD).

    iBio Inc. (AMEX: IBIO)

    iBio Inc. (AMEX: IBIO) Shares headed falling, lower as much as -1.44%. The most recent rating by Alliance Global Partners, on June 26, 2020, is at a Buy. iBio Inc. (IBIO) earlier revealed it has appointed Dr. Alexandra Kropotova to its Board of Directors, effective as of October 14, 2020. Dr. Kropotova has also been chosen as a member of iBio’s new Science & Technology Committee, which shall be chaired by Dr. Philip Russell.

    Onconova Therapeutics Inc. (NASDAQ: ONTX)

    Onconova Therapeutics Inc. (NASDAQ: ONTX) last closed at $0.29, in a 52-week range of $0.10 to $1.56. Onconova Therapeutics Inc. (ONTX) earlier disclosed that Dr. Steven M. Fruchtman, President and Chief Executive Officer, will present a company update during the 2020 BIO Investor Forum Digital event taking place October 13-15. Dr. Fruchtman and Avi Oler, Senior VP, Corporate Development, will be available for 1×1 meetings scheduled through the Bio Partnering system.

    Moderna Inc. (NASDAQ: MRNA)

    Moderna Inc. (NASDAQ: MRNA) Shares headed falling, lower as much as -2.17%. The most recent rating by SVB Leerink, on September 08, 2020, is at an Underperform. Moderna Inc. (MRNA) has earlier disclosed the initiation of a rolling submission to Health Canada for mRNA-1273. This initiation follows positive results from a preclinical viral challenge study of mRNA-1273 and the positive interim analysis of the Phase 1 study of mRNA-1273 in healthy adults and older adults.

    Selecta Biosciences Inc. (NASDAQ: SELB)

    Selecta Biosciences Inc. (NASDAQ: SELB) rose 18.01% after gaining more than $0.38 on Friday. Selecta Biosciences Inc. (SELB) has earlier announced an agreement with IGAN Biosciences, Inc. The agreement is the Research License and Option agreement signed to study Selecta’s ImmTOR™ immune tolerance platform in combination with IGAN’s immunoglobulin A (IgA) protease for the treatment of IgA Nephropathy (IgAN).

    Immunomedics Inc. (NASDAQ: IMMU)

    Immunomedics Inc. (NASDAQ: IMMU) stock soar by 0.08% to $87.56. The most recent rating by Barclays, on May 05, 2020, is at an Overweight. Immunomedics Inc. (IMMU) disclosed that the Office of Orphan Products Development of the U.S. Food and Drug Administration (FDA) has granted Trodelvy orphan status for the treatment of adult and pediatric patients with glioblastoma.

    Clovis Oncology Inc. (NASDAQ: CLVS)

    Clovis Oncology Inc. (NASDAQ: CLVS) fall -0.75% after losing more than -$0.05 on Friday. Clovis Oncology Inc. (CLVS) share price went from a low point around $2.93 to briefly over $17.37 in the past 52 weeks. It has moved up 102.56% from its 52-weeks low and moved down -65.83% from its 52-weeks high. CLVS market cap has remained high, hitting $532.72 million at the time of writing.

    Inovio Pharmaceuticals Inc. (NASDAQ: INO)

    Inovio Pharmaceuticals Inc. (NASDAQ: INO) stock drop by -2.95% to $11.85. The most recent rating by Maxim Group, on September 28, 2020, is at a Buy. Inovio Pharmaceuticals Inc. (INO) share price went from a low point around $2.09 to briefly over $33.79 in the past 52 weeks. It has moved up 456.84% from its 52-weeks low and moved down -65.56% from its 52-weeks high. INO market cap has remained high, hitting $2.05 Billion at the time of writing.

    MannKind Corporation (NASDAQ: MNKD)

    MannKind Corporation (NASDAQ: MNKD) last closed at $2.00, in a 52-week range of $0.80 to $2.48. MannKind Corporation (MNKD) has moved up 157.08% from its 52-weeks low and moved down -17.07% from its 52-weeks high. MNKD market cap has remained high, hitting $441.20 Million at the time of writing.

  • iBio (IBIO) Announces Deal With Safi Biosolutions To Develop Cytokines And Growth Factors

    iBio (IBIO) Announces Deal With Safi Biosolutions To Develop Cytokines And Growth Factors

    iBio, Inc. (AMEX: IBIO) soared 5.85% after the company has signed a Master Service Agreement with Safi Biosolutions, Inc. to develop cytokines and growth factors using the FastPharming system. As per the agreement, Safi will assess the FastPharming system of iBio for the checking of key proteins to be used in the bioprocessing of Safi blood cell therapy products.

    After the agreement, the pharmaceutical and development teams of iBio will work with Safi to evaluate options to use iBio’s FastPharming System to generate cGMP growth factors and cytokines. Safi a biotech company aimed to produce blood on demand which is a national priority and now becomes the first priority of Safi Biosolutions, Inc.

    The company’s initial development efforts for manufactured blood cell therapies include red blood cells for trauma, modified red blood cells for specific transfusion indications, and a neutrophil progenitor cell therapy for the treatment of chemotherapy-induced neutropenia. Safi turned to iBio’s plant-based protein expression system.

    iBio, Inc. (AMEX: IBIO) shares were trading up 5.85% at $2.17 at the time of writing on Friday. iBio, Inc. (AMEX: IBIO) share price went from a low point around $0.05 to briefly over $7.45 in the past 52 weeks, though shares have since pulled back to $2.17. It has moved up 4240.00% from its 52-weeks low and moved down -70.87% from its 52-weeks high. IBIO market cap has remained high, hitting $331.75 million at the time of writing.

    Furthermore, iBio Inc has announced that it has decided to invest $1.5 million in Safi in the form of a convertible promissory note. The company revealed that the convertible promissory note will have an interest rate of 5% per annum and will be fully convertible into common shares of Safi, at the option of iBio under certain circumstances.

  • 20 Trending Stocks In Biotechnology Industry You Should Consider Buying

    20 Trending Stocks In Biotechnology Industry You Should Consider Buying

    Investors are always looking for safe and secure investments and as a strong and profitable industry, the biotechnology industry is considered to be an attractive area of investment. This industry has experienced massive growth in recent years and is continuously adopting new technological advancements to keep pace with the fast-growing market. Biotechnology is a set of tools that uses living organisms to create or change a product, improve plants, trees, or animals, or develop microorganisms for specific uses.

    Modern Biotechnology’s main focus is on medicine. The companies in this sector are involved in the development of new treatments for various complex diseases. Technology has always been at the heart of the biotechnology industry. As the new technologies emerged with the passage of time the efficiency of companies has also improved. Similarly, technological advancements have also changed the clinical trial process.

    There are various other trends that the companies are following. Let see the top 20 companies in the biotechnology industry to get a better view:

    Cassava Sciences Inc. (NASDAQ: SAVA)

    Cassava Sciences Inc. (NASDAQ: SAVA) last closed at $11.47, in a 52-week range of $1.05 to $11.25. Analysts have a consensus price target of $17.00. Cassava Sciences Inc. (SAVA) has earlier announced the results of the Phase 2b study with its drug candidate Sumifilam, in Alzheimer’s disease. The clinical study which has received the funding by the National Institutes of Health (NIH) has shown the improvement in Alzheimer’s disease. Cassava Sciences Inc. (SAVA) market cap has remained high, hitting $242.02 M at the time of writing.

    Inovio Pharmaceuticals Inc. (NASDAQ: INO)

    Inovio Pharmaceuticals Inc. (NASDAQ: INO) stock soar by 10.21% to $16.94. The most recent rating by ROTH Capital, on July 01, 2020, is at a Sell. Inovio Pharmaceuticals Inc. (INO) has revealed that the US Food and Drug Administration (FDA) has informed the company that it has some questions related to the Phase 2/3 trial of its COVID-19 vaccine candidate INO-4800, including its CELLECTRA 2000 delivery device to be used in the trial. the company said that it will halt the trial until it clear all the ambiguities of FDA.

    Sorrento Therapeutics Inc. (NASDAQ: SRNE)

    Sorrento Therapeutics Inc. (NASDAQ: SRNE) Shares headed rising, higher as much as 4.84%. The most recent rating by H.C. Wainwright, on July 31, 2020, is at a Buy. Sorrento Therapeutics Inc. (SRNE) has earlier revealed the results of its’ multicenter, open-label, Phase 1b Study to Evaluate Safety and MTD of Epidural Resiniferatoxin Injection for the Treatment of Intractable Cancer Pain at the 14th Annual Pain Therapeutics Summit. The company has reported the encouraging results from its Phase 1b study to evaluate Epidural Resiniferatoxin Injection.

    Vaxart Inc. (NASDAQ: VXRT)

    Vaxart Inc. (NASDAQ: VXRT) rose 7.40% after gaining more than $0.51 on Friday. Pomerantz LLP is investigating claims on behalf of investors of Vaxart, Inc. Vaxart Inc. share price went from a low point around $0.25 to briefly over $17.49 in the past 52 weeks, though shares have since pulled back to $7.40. Vaxart Inc.’s market cap has remained high, hitting $752.43 M at the time of writing.

    Novavax Inc. (NASDAQ: NVAX)

    Novavax Inc. (NASDAQ: NVAX) stock soar by 10.86% to $113.56. The most recent rating by H.C. Wainwright, on August 06, 2020, is at a Buy. Par Sterile Products, LLC (Par Sterile) has entered into a non-exclusive agreement with Novavax, Inc. to provide fill-finish manufacturing services at its plant in Rochester, Michigan for NVX-CoV2373, Novavax’ COVID-19 vaccine candidate.

    Onconova Therapeutics Inc. (NASDAQ: ONTX)

    Onconova Therapeutics Inc. (NASDAQ: ONTX) Shares headed falling, lower as much as -3.23%. The most recent rating by H.C. Wainwright, on March 01, 2018, is at a Buy. Onconova Therapeutics Inc. (ONTX) earlier revealed that it has started the Phase 1 clinical trial in China for ON 123300 by its partner, HanX Biopharmaceuticals. Onconova has partnered with HanX Biopharmaceuticals in December 2017 for the development, registration, and commercialization of ON 123300 in China.

    Jaguar Health Inc. (NASDAQ: JAGX)

    Jaguar Health Inc. (NASDAQ: JAGX) last closed at $0.31, in a 52-week range of $0.29 to $1.38. Jaguar Health Inc. (JAGX) earlier revealed itis scheduled to participate in its first “Diarrhea Dialogues” virtual event on October 20 from 3:00 PM. The event, open to the financial and business community, will discuss the importance of supportive care for cancer patients as it relates to chronic lower GI tract distress, specifically with regard to debilitating diarrhea experienced as a result of cancer therapy.

    Zogenix Inc. (NASDAQ: ZGNX)

    Zogenix Inc. (NASDAQ: ZGNX) stock drop by -1.46% to $17.50. The most recent rating by Raymond James, on August 25, 2020, is at an Mkt perform. Zogenix Inc. (ZGNX) has revealed the pricing of its offering of $200,000,000 aggregate principal amount of 2.75% convertible senior notes due 2027 in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended.

    Trevena Inc. (NASDAQ: TRVN)

    Trevena Inc. (NASDAQ: TRVN) Shares headed rising, higher as much as 4.04%. The most recent rating by Guggenheim, on September 14, 2020, is at a Buy. Trevena Inc. (TRVN) has earlier participated in three presentations at the virtual 2020 American College of Clinical Pharmacology (ACCP) Annual Meeting. The meetings have taken place from September 21st to 23rd, 2020.

    VBI Vaccines Inc. (NASDAQ: VBIV)

    VBI Vaccines Inc. (NASDAQ: VBIV) last closed at $3.08, in a 52-week range of $0.47 to $6.93. VBI Vaccines Inc. (VBIV) is scheduled to participate in upcoming presentations including Sci-B-Vac: Results on Ph3 Hep B vaccine, Targeting CMV for the development of effective GBM immunotherapy on September 29 and 30, 2020, respectively. It has today participated in the COVID-19 panel discussion on the topic: What existing treatments and vaccine development platforms show promise to control the rate of infection and spread?

    Brickell Biotech Inc. (NASDAQ: BBI)

    Brickell Biotech Inc. (NASDAQ: BBI) Shares headed rising, higher as much as 3.90%. The most recent rating by Lake Street, on August 28, 2020, is at a Buy. Brickell Biotech Inc. (BBI) has revealed that its Japanese development partner, Kaken Pharmaceutical Co., Ltd. has received approval to manufacture and market sofpironium bromide gel, 5% under the brand name ECCLOCK in Japan for the treatment of primary axillary (underarm) hyperhidrosis.

    VYNE Therapeutics Inc. (NASDAQ: VYNE)

    VYNE Therapeutics Inc. (NASDAQ: VYNE) Shares headed falling, lower as much as -6.17%. VYNE Therapeutics Inc. (VYNE) has revealed that the Company will host a physician symposium on AMZEEQ and ZILXI™ on Thursday, October 1, 2020. VYNE market cap has remained high, hitting $271.70-M at the time of writing.

    Acorda Therapeutics Inc. (NASDAQ: ACOR)

    Acorda Therapeutics Inc. (NASDAQ: ACOR) shares were trading up 30.13% at $0.62 at the time of writing on Friday. Acorda Therapeutics Inc. (NASDAQ: ACOR) share price went from a low point around $0.42 to briefly over $3.27 in the past 52 weeks, though shares have since pulled back to $0.62. ACOR market cap has remained high, hitting $22.70M at the time of writing, giving it a price-to-sales ratio of more than 0. If we look at the recent analyst rating ACOR, H.C. Wainwright downgraded coverage on ACOR shares with a Neutral rating.

    Moderna Inc. (NASDAQ: MRNA)

    Moderna Inc. (NASDAQ: MRNA) last closed at $69.47, in a 52-week range of $13.53 to $95.21. Analysts have a consensus price target of $91.90. Moderna Inc. (MRNA) has moved up 413.45% from its 52-weeks low and moved down -327.03% from its 52-weeks high. Looking at its liquidity, it has a current ratio of 17.30. This company’s market capitalization has remained high, hitting $25.72 billion at the time of writing.

    iBio Inc. (AMEX: IBIO)

    iBio Inc. (AMEX: IBIO) rose 7.77% after gaining more than $0.15 on Friday. iBio Inc. (IBIO) share price went from a low point around $0.05 to briefly over $7.45 in the past 52 weeks, though shares have since pulled back to $2.08. iBio Inc. has moved up 4060.00% from its 52-weeks low and moved down -72.08% from its 52-weeks high.  IBIO market cap has remained high, hitting $336.61 M at the time of writing.

    Akebia Therapeutics Inc. (NASDAQ: AKBA)

    Akebia Therapeutics Inc. (NASDAQ: AKBA) rose 0.81% after gaining more than $0.02 on Friday.  In the past 52-weeks of trading, this company’s stock has fluctuated between the low of $2.34 and a high of $13.71. It has moved up 5.98% from its 52-weeks low and moved down -8191% from its 52-weeks high. Looking at its liquidity, it has a current ratio of 2.30. This company’s market capitalization has remained high, hitting $347.50 million at the time of writing.

    Vaccinex Inc. (NASDAQ: VCNX)

    Vaccinex Inc. (NASDAQ: VCNX) stock drop by -1.10% to $1.79. The most recent rating by BTIG Research, on September 23, 2020, is at a Neutral. Vaccinex Inc. (VCNX) share price went from a low point around $1.70 to briefly over $12.23 in the past 52 weeks, though shares have since pulled back to $1.79. VCNX has moved up 5.29% from its 52-weeks low and moved down -85.36% from its 52-weeks high.  VCNX market cap has remained high, hitting $36.19M at the time of writing.

    Ocugen Inc. (NASDAQ: OCGN)

    Ocugen Inc. (NASDAQ: OCGN) rose 2.29% after gaining more than $0.0 on Friday. In the past 52-weeks of trading, this company’s stock has fluctuated between the low of $0.17 and a high of $16.80. It has moved up 78.53% from its 52-weeks low and moved down -98.19% from its 52-weeks high. Looking at its liquidity, it has a current ratio of 3.30. This company’s market capitalization has remained high, hitting $40.03 million at the time of writing.

    9 Meters Biopharma Inc. (NASDAQ: NMTR)

    9 Meters Biopharma Inc. (NMTR) last closed at $0.76, in a 52-week range of $0.37 to $1.22. 9 Meters Biopharma Inc. (NMTR) has moved up 106.59% from its 52-weeks low and moved down -37.33% from its 52-weeks high. Looking at its liquidity, it has a current ratio of 1.30. This company’s market capitalization has remained high, hitting $101.25 million at the time of writing.

    Clovis Oncology Inc. (NASDAQ: CLVS)

    Clovis Oncology Inc. (NASDAQ: CLVS) stock soar by 3.25% to $5.88. The most recent rating by H.C. Wainwright, on May 18, 2020, is at a Buy. Clovis Oncology Inc. (CLVS) share price went from a low point around $2.93 to briefly over $17.37 in the past 52 weeks, though shares have since pulled back to $5.88. CLVS has moved up 100.68% from its 52-weeks low and moved down -66.15% from its 52-weeks high.  CLVS market cap has remained high, hitting $502.33M at the time of writing.

     

  • Here’s Why You Should Avoid iBio (IBIO) Stocks For COVID-19 Vaccine

    Here’s Why You Should Avoid iBio (IBIO) Stocks For COVID-19 Vaccine

    All the companies involved in the production of the coronavirus vaccine, iBio is far behind from its competitors in the vaccine trial. The company has earlier revealed that it has selected IBIO-201, its LicKM-ubunit vaccine, as its leading candidate for the prevention of coronavirus infection. But the company has not provided any promising result related to its coronavirus vaccine candidate nor it entered into the human trial of its vaccine candidate.

    iBio, a biotech innovator and biologics contract manufacturing organization has earlier made the various claims about its vaccine candidate. It has claimed exclusive worldwide license agreement on a cure called ACE2-Fc from Planet  Biotechnology. Not only this, but the company also claimed that its FastPharming system has the ability to produce vaccines quickly using plant cells.

    So, it is better to avoid iBio for the coronavirus vaccine until it catches up and moves its coronavirus vaccine candidate into human trials. Many companies including Moderna, Novavax, AstraZeneca, and Pfizer all are currently in human trials of their vaccine candidate. But iBio, Inc. is still in the lab and far behind from its competitors. To reach the market human trials are necessary.

    Shares of iBio, Inc. (IBIO) traded up 9.30% as it gained +0.20 on Thursday. In the past 52-weeks of trading, this company’s stock has fluctuated between the low range of $0.05 and a high range of $7.45. iBio has moved up 4600.00% from its 52-weeks low and moved down -68.46% from its 52-weeks high. Looking at its profitability, its return on assets and investment is -108.70%, and -57.60%, respectively. If we turn our focus on its liquidity, its current ratio is 1.70. iBio, Inc. market capitalization has remained high, hitting $420.46 million at the time of writing.

    There are various sciences behind iBio stock. If we look at the political stories, Donald Trump is looking for a vaccine before November. Similarly, from a business point of view, billions were given to the companies for the products which are not ready for the market yet. If we turn our focus on iBio, it only claims that it has a vaccine candidate but that is still in the lab.

    It has not advanced it trial to humans which is necessary. iBio stocks soared after it revealed about the FastPharming. But it is not clear yet whether the company has a vaccine or not or it is the trick of the company to excite its stock. So, it is better to avoid the stock of iBio for the coronavirus vaccine until it starts a human trial.